Fig. 5

NF-κB is involved in the potentiation of MMP-3 production by CX3CL1. a–c OASFs were pretreated for 30 min with PDTC (10 μM) and TPCK (10 μM) followed by stimulation with CX3CL1 for 24 h. MMP-3 expression examined using qPCR, western blot analysis, and ELISA. d OASFs were incubated with CX3CL1 for the indicated time intervals. p-IKKα/β, p-IκBα, and p-p65 expression determined using western blot analysis. e, f OASFs were transfected for 24 h with IKKα and IKKβ mutants followed by stimulation with CX3CL1 for 24 h. MMP-3 expression examined using qPCR and ELISA. Results expressed as mean ± SEM (n = 3). *p < 0.05 compared with control; #p < 0.05 compared with CX3CL1-treated group. MMP matrix metalloproteinase, PDTC pyrrolidine dithiocarbamate, TPCK l-1-tosylamido-2-phenylenylethyl chloromethyl ketone